Publications
239 results found
Loupy A, Haas M, Roufosse C, et al., 2020, The banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection., American Journal of Transplantation, Vol: 20, Pages: 2318-2331, ISSN: 1600-6135
The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell-mediated rejection (TCMR), borderline, and antibody-mediated rejection (ABMR). The main focus of kidney sessions was on how to address biopsies meeting criteria for CA TCMR plus borderline or acute TCMR. Recent studies on the clinical impact of borderline infiltrates were also presented to clarify whether the threshold for interstitial inflammation in diagnosis of borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing microvascular inflammation in the absence of C4d staining or detectable donor-specific antibodies; the potential value of molecular diagnostics in such cases and recommendations for use of the latter in the setting of solid organ transplantation are presented in the accompanying meeting report. Finally, several speakers discussed the capabilities of artificial intelligence and the potential for use of machine learning algorithms in diagnosis and personalized therapeutics in solid organ transplantation.
Prendecki M, Clarke C, Cairns T, et al., 2020, Anti-glomerular basement membrane disease during the COVID-19 pandemic, Kidney International, ISSN: 0085-2538
Hanley B, Roufosse CA, Osborn M, et al., 2020, Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date., British Journal of Haematology, Vol: 189, Pages: 1062-1063, ISSN: 0007-1048
Shiu KY, Stringer D, McLaughlin L, et al., 2020, Effect of optimized immunosuppression (including rituximab) on anti-donor alloresponses in patients with chronically rejecting renal allografts, Frontiers in Immunology, Vol: 11, Pages: 1-16, ISSN: 1664-3224
RituxiCAN-C4 combined an open-labeled randomized controlled trial (RCT) in 7 UK centers to assess whether rituximab could stabilize kidney function in patients with chronic rejection, with an exploratory analysis of how B cell-depletion influenced T cell anti-donor responses relative to outcome. Between January 2007 and March 2015, 59 recruits were enrolled after screening, 23 of whom consented to the embedded RCT. Recruitment was halted when in a pre-specified per protocol interim analysis, the RCT was discovered to be significantly underpowered. This report therefore focuses on the exploratory analysis, in which we confirmed that when B cells promoted CD4+ anti-donor IFNγ production assessed by ELISPOT, this associated with inferior clinical outcome; these patterns were inhibited by optimized immunosuppression but not rituximab. B cell suppression of IFNγ production, which associated with number of transitional B cells and correlated with slower declines in kidney function was abolished by rituximab, which depleted transitional B cells for prolonged periods. We conclude that in this patient population, optimized immunosuppression but not rituximab promotes anti-donor alloresponses associated with favorable outcomes.
Osman B, Alam H, Roufosse C, et al., 2019, INDICATIONS AND OUTCOME OF PATIENTS UNDERGOING VERY LATE RENAL TRANSPLANT BIOPSIES, Publisher: WILEY, Pages: 210-211, ISSN: 0934-0874
Poo SX, Tham CSW, Smith C, et al., 2019, IgG4-related disease in a multi-ethnic community: Clinical characteristics and association with malignancy, QJM: An International Journal of Medicine, Vol: 112, Pages: 763-769, ISSN: 1460-2393
BackgroundImmunoglobulin-G4-related disease (IgG4-RD) is a recently recognised fibro-inflammatory condition that can affect multiple organs. Despite growing interest in this condition, the natural history and management of IgG4-RD remain poorly understood.AimTo describe the clinical characteristics, treatment and outcomes of IgG4-RD in a multi-ethnic UK cohort, and investigate its possible association with malignancy.DesignRetrospective analysis of case-note and electronic data.MethodsCases were identified from sub-specialty cohorts and a systematic search of an NHS trust histopathology database using ‘IgG4’ or ‘inflammatory pseudotumour’ as search terms. Electronic records, imaging and histopathology reports were reviewed.Results66 identified cases of IgG4-RD showed a similar multi-ethnic spread to the local population of North West London. The median age was 59 years and 71% of patients were male. Presenting symptoms relating to mass effect of a lesion were present in 48% of cases and the mean number of organs involved was 2.4. 10 patients had reported malignancies with 6 of these being haematological. 83% of those treated with steroids had good initial response, however 50% had relapsing-remitting disease. Rituximab was administered in 11 cases and all achieved an initial serological response. Despite this, 7 patients subsequently relapsed after a mean duration of 11 months and 4 progressed despite treatment.ConclusionsWe report a large UK-based cohort of IgG4-RD that shows no clear ethnic predisposition and a wide range of affected organs. We discuss the use of serum IgG4 concentrations as a disease marker in IgG4-RD, the association with malignant disease and outcomes according to differing treatment regimens.
Seneschall C, Ghazy A, Roufosse C, et al., 2019, LYMPHOCYTIC TUBULITIS COMMONLY CO-EXISTS WITH RENAL ALLOGRAFT PYELONEPHRITIS AND OPTIMAL MANAGEMENT IS UNKNOWN, Publisher: WILEY, Pages: 379-380, ISSN: 0934-0874
Kousios A, Roufosse C, 2019, An update on paraprotein-related renal pathology, Diagnostic Histopathology, Vol: 25, Pages: 408-421, ISSN: 1756-2317
Paraproteins are intact monoclonal immunoglobulins (MIg) or isolated MIg heavy or light chains, detected in the blood or urine and caused by a clonal proliferation of B cells or plasma cells. Paraproteins often cause renal injury, referred to here as paraprotein-related renal disease (PPRD), whether the underlying clonal disorder is characterized by high tumour burden requiring treatment or low tumour burden and thus not requiring immediate treatment from the haematological standpoint. For the latter, an important recent update is the introduction of the concept of Monoclonal Gammopathy of Renal Significance (MGRS), in which the renal pathology in itself may justify the use of clone-directed therapies targeting the nephrotoxic clone, in order to preserve renal function. A bewildering array of renal pathology can be caused by paraproteins, affecting all compartments of the kidney – glomeruli, tubules, interstitium and blood vessels. This review aims to provide an overview of the different renal lesions that can be seen, organized by predominant compartment affected, with guidance on how to spot them and classify them.
Nikolopoulou A, Condon M, Turner-Stokes T, et al., 2019, Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: A randomised controlled trial., BMC Nephrology, Vol: 20, Pages: 1-9, ISSN: 1471-2369
Background: Tacrolimus (TAC) is effective in treating membranous nephropathy (MN);however relapses are frequent after treatment cessation. We conducted a randomisedcontrolled trial to examine whether the addition of mycophenolate mofetil (MMF) to TACwould reduce relapse rate.Methods: 40 patients with biopsy proven idiopathic MN and nephrotic syndrome wererandomly assigned to receive either TAC monotherapy (n=20) or TAC combined with MMF(n=20) for 12 months. When patients had been in remission for 1 year on treatment the MMFwas stopped and the TAC gradually withdrawn in both groups over 6 months. Patients alsoreceived supportive treatment with angiotensin blockade, statins, diuretics andanticoagulation as needed. Primary endpoint was relapse rate following treatmentwithdrawal. Secondary outcomes were remission rate, time to remission and change in renalfunction.Results: 16/20 (80%) of patients in the TAC group achieved remission compared to 19/20(95%) in the TAC/MMF group (p=0.34). The median time to remission in the TAC groupwas 54 weeks compared to 40 weeks in the TAC/MMF group (p=0.46). There was nodifference in the relapse rate between the groups: 8/16 (50%) patients in the TAC grouprelapsed compared to 8/19 (42%) in the TAC/MMF group (p=0.7). The addition of MMF toTAC did not adversely affect the safety of the treatment.Conclusions: Addition of MMF to TAC does not alter the relapse rate of nephrotic syndromein patients with MN.
Kousios A, Duncan N, Charif R, et al., 2019, Autologous stem cell transplant for the treatment of type I crystal cryoglobulinaemic glomerulonephritis caused by monoclonal gammopathy of renal significance (MGRS), Kidney International Reports, Vol: 4, Pages: 1342-1348, ISSN: 2468-0249
Cryoglobulins (CGs) are immunoglobulins that precipitate at temperatures below 37°C and dissolve again after rewarming. Cryoglobulinemia may be asymptomatic or cause end-organ damage by CG precipitation in small- to medium-sized blood vessels.1 In their seminal work, Brouet et al.2 classify cryoglobulinemias into 3 subgroups according to CG composition and clonality. In type II cryoglobulinemia there is a mixture of monoclonal IgM with rheumatoid factor activity and polyclonal IgG. In type III, CGs consist of polyclonal IgM and IgG.1 Type II and III cryoglobulinemias are also referred to as mixed cryoglobulinemias and are often caused by chronic hepatitis C infection and less frequently by autoimmune diseases or other viral infections (hepatitis B infection, HIV).3CGs in type I cryoglobulinemia are monoclonal Igs (MIg), also known as paraproteins, commonly IgG, IgM subtypes, or free light chains. The underlying pathological process is a plasma cell or B-cell lymphoproliferative disease, such as multiple myeloma (MM), Waldenström macroglobulinemia, chronic lymphocytic leukemia, or other B-cell non-Hodgkin lymphoma. However, in approximately 40% of symptomatic cases, the plasma cell or B-cell clone is too small to fulfill the diagnostic criteria of MM or overt lymphoma. The term monoclonal gammopathy of undetermined significance (MGUS) used for these cases is a misnomer, as the MIg causes disease regardless of the size and tumor burden.4 For cases with renal involvement, the International Kidney and Monoclonal Gammopathy Research Group introduced the term monoclonal gammopathies of renal significance (MGRS).5 The updated MGRS definition includes monoclonal gammopathies that cause renal disease but have low tumor burden and thus treatment from the hematological standpoint is not imminently indicated.6 These patients may have fewer than 10% plasma cells in bone marrow biopsy, smoldering myeloma, or low-grade lymphomas.7 MGRSs are not of undetermined significanc
Toulza F, Dominy K, Galliford J, et al., 2019, OR48 Gene expression analysis in renal transplant biopsies: Comparison of split samples and different techniques, American-Society-for-Histocompatibility-and-Immunogenetics (ASHI)/BANFF Joint Scientific Meeting, Publisher: Elsevier, Pages: 52-52, ISSN: 0198-8859
AimThe Banff Classification for Allograft Pathology includes increased expression of genes associated with antibody-mediated rejection (AMR) if thoroughly validated in the diagnostic criteria for AMR. There is limited information on how results of gene expression analysis are influenced by sample preservation (formalin-fixation versus RNA later) and gene analysis technique used. Our aim is to compare: 1) Nanostring analysis of samples from the same biopsy split for formalin fixation and paraffin embedding (FFPE) and RNAlater (RL); 2) Nanostring (NS) and Q-PCR of samples preserved in RL.MethodsWe used a custom panel of 219 genes on the NS platform and of 18 genes for Q-PCR. RNA was extracted from 51 renal transplant biopsies, either from the whole sample (RL), or from 3 × 20-micron sections (FFPE), using a Qiagen kit. Q-PCR was performed with SYBR Green quantification. Correlation was carried out using Spearman rank, with significance set at p < 0.01.ResultsComparing the expression of 219 genes using the NS platform between FFPE and RL samples from the same 51 biopsies, we found significant correlation of the expression of the 219 genes in 47/51 samples (92%) (p median = 4 × 10–12 [3 × 10-56-0.54]); and significant correlation of individual genes between the 2 samples in 163/219 genes (74%) (p median = 0.00003 [3.69 × 10-18-0.98]). Comparing the expression of 18 AMR-tagged genes using NS versus qPCR, from the same pool of RNA in RL (n = 51), we found significant correlation in 17/18 genes (94%) (p median = 0.032 [0.001–0.966]).ConclusionsMost biopsies (92%) can be split and preserved in FFPE or RL and show good correlation of gene expression results across a range of transcripts using a single platform (NS). However almost a quarter of individual genes showed poor correlation on the same platform (NS) between split samples from the same biopsy in FFPE and RL. This could be because there is genuine variation in levels of expressi
Tennekoon H, Kousios A, Gardiner R, et al., 2019, Anticoagulation related nephropathy in a post renal transplant patient, Publisher: SPRINGER, Pages: S373-S373, ISSN: 0945-6317
Roufosse C, Simmonds N, Clahsen-van Groningen M, et al., 2019, DIFFICULTIES IN THE APPLICATION OF THE BANFF CLASSIFICATION OF KIDNEY ALLOGRAFT PATHOLOGY, American-Society-for-Histocompatibility-and-Immunogenetics (ASHI)/BANFF Joint Scientific Meeting, Publisher: ELSEVIER SCIENCE INC, Pages: 226-226, ISSN: 0198-8859
Reid G, Boils C, Bu L, et al., 2019, MOLECULAR CHARACTERIZATION OF IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED RENAL ALLOGRAFT REJECTION: OVERLAP WITH NATIVE KIDNEY ACUTE INTERSTITIAL NEPHRITIS, American-Society-for-Histocompatibility-and-Immunogenetics (ASHI)/BANFF Joint Scientific Meeting, Publisher: ELSEVIER SCIENCE INC, Pages: 53-53, ISSN: 0198-8859
Tennekoon H, Cook T, Palmer A, et al., 2019, Congophilic fibrillary glomerulonephritis, Publisher: SPRINGER, Pages: S373-S373, ISSN: 0945-6317
Navaratnarajah A, Sambasivan K, Cook TH, et al., 2019, Predicting long-term renal and patient survival by clinicopathological features in elderly patients undergoing a renal biopsy in a UK cohort, Clinical Kidney Journal, Vol: 12, Pages: 512-520, ISSN: 2048-8505
Background: Several publications have demonstrated the use of renal biopsy in elderly patients in establishing a diagnosis and enabling directed therapy. However, evidence on the long-term outcomes following biopsies is lacking. The aim of this study is to describe the renal and patient outcomes in elderly patients according to indication for biopsy, clinical parameters and the histological diagnosis. Methods: We performed a retrospective cohort study of 463 patients >70 years old who underwent a renal biopsy at our centre between 2006 and 2015. Results: The median age of the patients was 74.8 (range 70.0-89.6) years. The most frequent primary diagnoses were pauci-immune crescentic glomerulonephritis (GN; 12%), acute interstitial nephritis (10.8%) and membranous GN (7.1%). Death-censored renal survival at 1 and 5 years following the index biopsy was 85.2 and 75.9%, respectively, and patient survival at 1 and 5 years was 92.2 and 71.6%, respectively. Patients who progressed to end-stage renal disease (ESRD) were at higher risk of dying compared with patients who did not require dialysis [hazard ratio 2.41 (95% confidence interval 1.58-3.68; P < 0.001]. On multivariate analysis, factors associated with the risk of progression to ESRD were creatinine (P < 0.001), heavy proteinuria (P = 0.002) and a non-chronic kidney disease (CKD) biopsy indication (P = 0.006). A histological diagnosis of primary GN (P = 0.001) or tubulointerstitial nephritis (P = 0.008) was associated with a favourable renal outcome, while patients with vasculitis and paraprotein-related renal disease (PPRD) had the highest risk of requiring dialysis (P = 0.0002 and P = 0.003, respectively). PPRD was also an independent risk factor for death. Conclusions: This study demonstrates that renal biopsies in the elderly not only enable directed therapy, but also provide prognostic i
Broecker V, Bardsley V, Torpey N, et al., 2019, Clinical-pathological correlations in post-transplant thrombotic microangiopathy, Histopathology, Vol: 75, Pages: 88-103, ISSN: 0309-0167
AimsPost‐transplant thrombotic microangiopathy (TMA) is a rare and clinically challenging finding in renal transplant biopsies. In addition to recurrent atypical haemolytic uraemic syndrome, TMA in renal transplants is associated with various conditions, such as calcineurin inhibitor (CNI) treatment, antibody‐mediated rejection (ABMR), viral infections, sepsis, pregnancy, malignancies, and surgery. The therapeutic implications of this diagnosis are considerable. In order to better understand post‐transplant TMA and to identify histological or clinical differences between associated causes, we conducted a multicentre retrospective study.Methods and resultsClinical parameters and transplant renal biopsy findings from 81 patients with TMA were analysed. Biopsies from 38 patients were also analysed with electron microscopy. On the basis of clinical–pathological correlation, TMA was attributed to a main aetiology, whenever possible. TMA occurred at a median of 30 days post‐transplantation. Systemic features of TMA were present in only 18% of cases. Twenty‐two per cent of cases were attributed to CNI and 11% to ABMR. Although other potentially contributing factors were found in 56% of patients, in most cases (63%) no clearly attributable cause of TMA was identified. Histological differences between groups were minimal. The detection of ultrastructural features that are usually associated with ABMR may help to establish ABMR as the cause of TMA.ConclusionsAlthough CNI and ABMR appear to be the main contributors to post‐transplant TMA, the aetiology of most cases is probably multifactorial, and TMA cannot be unequivocally attributed to a single underlying aetiology. Morphological features of TMA are not discriminating, but electron microscopy may help to identify ABMR‐associated TMA.
Hassan S, Regan F, Brown C, et al., 2019, Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post renal transplantation, American Journal of Transplantation, Vol: 19, Pages: 1720-1729, ISSN: 1600-6135
De novo HLA donor specific antibodies (DSA) following transplantation are associated with alloimmune injury and allograft failure. Blood transfusions are allogeneic, and when given post-transplant (PTBT) they may independently increase the risk of HLA antibody development. This study aims to analyse the development of HLA transfusion specific antibodies (TSA) to blood donors of transfusions given post-transplant and examine the impact on clinical outcomes. 244 blood donors of transfusions received by 86 transplant patients (46 who developed a DSA post transfusion and 40 who remained DSA negative) were HLA typed. De novo TSA developed against 150/244(61.5%) blood donors. In 70/150(46.7%) cases the TSA was of shared HLA antibody specificity with a DSA response in the recipient (DSA+=TSA+). This occurred when there was a greater overall HLA match between the blood and transplant donor. DSA+=TSA+ patients had increased risk of allograft failure [p=0·0025] and AMR [p=0·02] compared with the DSA+≠TSA+ patients. To conclude, PTBT may elicit de novo HLA antibodies. Enhanced HLA matching between the blood and transplant donor is more likely to result in a DSA and TSA of shared antibody specificities. Transfusion avoidance or the use of HLA matched or selected blood may reduce this risk and improve outcomes.
Kousios A, Storey R, Troy-Barnes E, et al., 2019, Plasmacytoma-like post-transplant lymphoproliferative disease in a disused arterio-venous fistula: the importance of histopathology., Kidney International Reports, Vol: 4, Pages: 749-755, ISSN: 2468-0249
Common causes of swelling in arteriovenous fistulae (AVFs) include thrombosis, infection, aneurysm, and superior vena cava (SVC) obstruction secondary to previous dialysis vascular catheter use. Malignancies confined in AVFs are rare and have been described in case series and case reports, mostly in immunosuppressed patients.1 Patients who undergo transplantation frequently have functioning or nonfunctioning AVFs. The risk of malignancy is increased in this patient group and thus should be considered in patients presenting with symptomatic AVF. The most common histopathological diagnosis is angiosarcoma.1, 2 Plasmacytoma-like posttransplant lymphoproliferative disease (PTLD) confined in an AVF has not been previously described.
Randhawa P, Roufosse C, 2019, The expanding spectrum of antibody-mediated rejection: should we include cases where no anti-HLA donor-specific antibody is detected?, American Journal of Transplantation, Vol: 19, Pages: 622-624, ISSN: 1600-6135
Antibody-mediated rejection (ABMR) in a renal transplant biopsy is most often diagnosed by a combination of microvascular injury (MVI), C4d deposition and presence of circulating DSA. MVI designates the leucocyte margination reaction in glomeruli (glomerulitis, Banff score g) and in peritubular capillaries (peritubular capillaritis, Banff score ptc). MVI (sum of Banff scores g+ptc) is a morphological feature rather than a diagnosis, and is not specific for ABMR.
Kousios A, Duncan N, Tam FWK, et al., 2019, Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!, Kidney International, Vol: 95, Pages: 467-468, ISSN: 0085-2538
Koutroutsos K, Charif R, Moran L, et al., 2019, Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab, Clinical and Experimental Nephrology, ISSN: 1342-1751
BACKGROUND: Post-transplant focal segmental glomerulosclerosis (FSGS) is associated with renal allograft loss. Currently, optimal treatment remains controversial. METHODS: The aim of our study was to examine the efficacy and safety of therapeutic plasma exchange (TPE), and rituximab (RTX), in the management of post-transplant FSGS. The treatment protocol consisted of RTX and monthly cycles of 5 plasma exchanges for 6 months. We treated 10 transplant recipients with biopsy-proven post-transplant FSGS. Lastly, we compared the studied group to a historic control group of nine patients with post-transplant FSGS. RESULTS: 9 out of 10 patients achieved remission after the conclusion of treatment (4 complete and 5 partial), while 1 patient did not respond to treatment. During the follow-up period, there was one graft loss and one patient died while in remission from unrelated complications. There was a significant reduction in mean uPCR between diagnosis (517.4 ± 524.2 mg/mmol) and last follow-up (87 ± 121.6 mg/mmol) in the patients with sustained remission (p = 0.026). There was no significant decline in eGFR in the eight relapse-free responders at the end of follow-up. (54.4 ± 16.7 from 49.8 ± 20.4 ml/min) (p = 0.6) An increased response rate to the combined TPE and RTX treatment was demonstrated, when compared to a historic control group of nine patients with post-transplant FSGS, as only five out of nine patients achieved remission (two complete and three partial) in that group. CONCLUSIONS: In this study, treatment with TPE and RTX appears to be safe, well tolerated and effective in the management of patients with post-transplant FSGS.
Dominy KM, Willicombe M, Al Johani T, et al., 2019, Molecular assessment of C4d positive renal transplant biopsies without evidence of rejection, Kidney International Reports, Vol: 4, Pages: 148-158, ISSN: 2468-0249
IntroductionImmunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) is unknown. We investigated the transcript levels of genes associated with AbMR in C4d+ WER biopsies from both ABO-compatible and incompatible renal transplant patients.MethodsRNA was extracted from formalin-fixed paraffin-embedded renal transplant biopsies (n = 125) and gene expression analysis of 35 AbMR-associated transcripts carried out using the NanoString nCounter system.ResultsAbMR-associated transcripts were significantly increased in samples with AbMR or suspicious AbMR. A subgroup of 17 of 35 transcripts that best distinguished AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ WER samples. There was no differential expression between C4d-negative and C4d+ WER from both ABO-incompatible and -compatible transplants. The geometric mean of 17 differentially expressed genes was used to assign the C4d+ WER biopsies a high- or low-AbMR transcript score. Follow-up biopsies showed AbMR within 1 year of initial biopsy in 5 of 7 high-AbMR transcript patients but only 2 of 46 low-AbMR transcript patients. In multivariate logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were associated with increased odds for biopsy-proven AbMR on follow-up (P = 0.032, odds ratio 16.318), whereas factors including donor-specific antibody (DSA) status and time since transplantation were not.ConclusionGene expression analysis in C4d+ WER samples has the potential to identify patients at higher risk of developing AbMR.
Roufosse C, Simmonds N, Clahsen-van Groningen M, 2018, A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology (vol 102, pg 1795, 2018), TRANSPLANTATION, Vol: 102, Pages: E497-E497, ISSN: 0041-1337
Kousios A, Duncan N, Charif R, et al., 2018, Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity, JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, Vol: 29, Pages: 2901-2901, ISSN: 1046-6673
Roufosse CA, Becker J, Clahsen van Groningen M, et al., 2018, A 2018 reference guide to the Banff classification of renal allograft pathology., Transplantation, Vol: 102, Pages: 1795-1814, ISSN: 0041-1337
The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of biopsies from solid organ transplants. Since its initial conception in 1991 for renal transplants, it has undergone review every 2 years, with attendant updated publications. The rapid expansion of knowledge in the field has led to numerous revisions of the classification. The resultant dispersal of relevant content makes it difficult for novices and experienced pathologists to faithfully apply the classification in routine diagnostic work and in clinical trials.This review shall provide a complete and simple illustrated reference guide of the Banff Classification of Kidney Allograft Pathology based on all publications including the 2017 update. It is intended as a concise desktop reference for pathologists and clinicians, providing definitions, Banff Lesion Scores and Banff Diagnostic Categories. An on-line website reference guide hosted by the Banff Foundation for Allograft Pathology (www.banfffoundation.org) is being developed, which will be updated with future refinement of the Banff Classification from 2019 onwards.
Roufosse CA, Webster P, Moss J, et al., 2018, Familial Fibrillary Glomerulonephritis with Positive Immunohistochemistry for DNAJB9, 11th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY, Pages: S38-S38, ISSN: 0022-3417
Elshiekh M, Trivedi P, Roufosse C, et al., 2018, Renal intravascular NK/T cell lymphoma; a case report, Publisher: SPRINGER, Pages: S266-S266, ISSN: 0945-6317
Roufosse CA, Willicombe M, Galliford J, et al., 2018, C4d Positive Renal Transplant Biopsies With No other Evidence of Rejection: Transcriptional Investigation of Biological Significance Using Nanostring nCounter Technology, 11th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY, Pages: S18-S18, ISSN: 0022-3417
Kousios A, Brah T, Troy-Barnes E, et al., 2018, The Histopathological Spectrum of Monoclonal Gammopathies of Renal Significance: A Single Centre Experience, 11th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY, Pages: S19-S19, ISSN: 0022-3417
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.